Skip to main
VNRX

Volitionrx Limited (VNRX) Stock Forecast & Price Target

Volitionrx Limited (VNRX) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

VolitionRX is a promising company with a unique focus on using Nucleosomics to develop simple and effective blood tests for early detection and monitoring of a variety of diseases, including cancer. The recent announcement of a high sensitivity rate for early stage cancers in a blinded validation cohort highlights the potential of their technology and its possible applications in Multi-Cancer Early Detection and Minimal Residual Disease detection. Additionally, their focus on circulating cell free nucleoproteins and the potential for partnerships adds further value to the company.

Bears say

VolitionRX is facing a negative outlook due to ongoing concerns about its capital structure and investor confidence, as well as its ability to meet compliance requirements with NYSE American. Additionally, while the company has shown potential through its Nucleosomics platform and partnerships with top diagnostic and liquid biopsy companies, there is still uncertainty surrounding its ability to generate significant revenue and achieve clinical adoption. Other risk factors, such as regulatory and legal risks, also contribute to the negative outlook for the company.

Volitionrx Limited (VNRX) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Volitionrx Limited and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Volitionrx Limited (VNRX) Forecast

Analysts have given Volitionrx Limited (VNRX) a Strong Buy based on their latest research and market trends.

According to 4 analysts, Volitionrx Limited (VNRX) has a Strong Buy consensus rating as of Apr 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $2, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $2, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Volitionrx Limited (VNRX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.